Dovitinib lactate
A novel, multitargeted RTK inhibitor of class III, IV, and V RTKs with IC50 of 1/2/36/8/9 nM for FLT3/c-KIT/c-Fms/FGFR1/FGFR3, respectively; also inhibits VEGFR1/2/3 (IC50=10/13/8 nM) and PDGFRβ/α (IC50=27/210 nM) ; selectively inhibits the growth of B9 cells and human myeloma cell lines expressing wild-type (WT) or activated mutant FGFR3; inhibits downstream ERK 1/2 phosphorylation and induces cytostatic and cytotoxic effects; demonstrates activity in a xenograft mouse model of FGFR3 MM; orally active.Blood Cancer Phase 2 Clinical.
Product Specifications
CAS Number
692737-80-7
Product Name Alternative
CHIR-258 | TKI258 | TKI-258 | TKI 258 | CHIR258 | CHIR 258
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 30 mg/mL
Smiles
CC (C (=O) O) O.CN1CCN (CC1) C2=CC3=C (C=C2) N=C (N3) C4=C (C5=C (C=CC=C5F) NC4=O) N
Molecular Formula
C24H27FN6O4
Molecular Weight
482.5073832
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6- (4-methyl-1-piperazinyl) -1H-benzimidazol-2-yl]-2 (1H) -quinolinone (1:1)
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PISD CRISPR Knock Out 293T Cell Line (Human)